Intuitive Surgical (ISRG) Earnings Date & Reports

Key Takeaways

• Revenue reached $2.89 billion, up 19% year-over-year and ahead of the $2.81 billion consensus estimate.
• Non-GAAP earnings per share (EPS) came in at $2.80, beating analyst expectations of $2.48 by approximately 12.9%.
• Worldwide da Vinci procedures grew approximately 15%, while Ion robotic bronchoscopy procedures surged roughly 36% compared to the prior-year quarter.
• The company maintained its full-year da Vinci procedure growth guidance of 13.5% to 15.5%, disappointing investors who had hoped for a raise.
• Shares fell roughly 10% in after-hours trading as moderating U.S. procedure growth and unchanged guidance overshadowed the earnings beat.

Earnings Context and Why It Matters

Intuitive Surgical's second-quarter report, released after the market closed on July 16, 2026, carried significant weight for investors assessing the durability of the robotic surgery leader's growth trajectory. The company entered the quarter under pressure, with shares down roughly 30% year-to-date amid concerns that GLP-1 weight-loss drugs could erode bariatric surgery volumes and that longer instrument lifespans might pressure recurring revenue. This report served as a critical checkpoint for whether Intuitive's da Vinci 5 upgrade cycle and international expansion could offset those headwinds. As the dominant player in robotic-assisted surgery with nearly 13,000 systems installed worldwide, Intuitive's results also offer a read on broader hospital capital spending trends and surgical procedure demand globally.

Reported Results

Intuitive Surgical reported second-quarter 2026 revenue of $2.89 billion, reflecting a 19% increase from $2.44 billion in the second quarter of 2025 and surpassing the consensus estimate of approximately $2.81 billion. Revenue growth was driven by higher procedure volumes, an expanding installed base of da Vinci and Ion systems, and increased system leasing revenue.

On a GAAP (Generally Accepted Accounting Principles) basis, net income attributable to Intuitive was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per share, in the prior-year period. Non-GAAP net income reached $1.00 billion, or $2.80 per diluted share, up from $798 million, or $2.19 per share, a year earlier. The non-GAAP EPS figure handily beat the consensus estimate of $2.48. Both GAAP and non-GAAP results included an $0.08 per share benefit tied to a $28 million net-of-tax refund of IEEPA (International Emergency Economic Powers Act) tariffs paid in prior periods.

Instruments and accessories revenue rose 18% to $1.73 billion, fueled by approximately 15% growth in da Vinci procedure volume and roughly 36% growth in Ion procedures. Systems revenue climbed to $685 million from $575 million a year ago, reflecting higher da Vinci system average selling prices (ASPs) and increased placements. The company placed 468 da Vinci surgical systems during the quarter, compared with 395 in the prior-year period, including 246 da Vinci 5 systems. Recurring revenue — consisting of instruments, accessories, leasing, and services — represented approximately 85% of total quarterly revenue, underscoring the resilience of Intuitive's razor-and-blade business model.

The company ended the quarter with $8.63 billion in cash, cash equivalents, and investments, up $0.65 billion sequentially, and repurchased 0.9 million shares for approximately $380 million during the quarter.

AI Screener

For investors tracking earnings-driven opportunities like Intuitive Surgical, Tickeron's AI Screener offers a practical way to navigate an increasingly complex market. The AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, and AI-driven signals. By surfacing breakout candidates, trending stocks, and emerging trade ideas more efficiently than manual screening, the screener can complement an earnings-focused research process. Exploring the AI Screener may help you identify the next high-conviction opportunity before the broader market catches on.

Market Reaction and Investor Sentiment

Despite headline results that exceeded both revenue and earnings expectations, Intuitive Surgical shares declined approximately 10% in after-hours trading on July 16. The negative reaction reflected investor disappointment that management maintained, rather than raised, its full-year 2026 da Vinci procedure growth guidance of 13.5% to 15.5%. This implied a potential deceleration in the second half of the year relative to the 15% growth posted in Q2.

Compounding the cautious sentiment, U.S. da Vinci procedure growth moderated to 12% — below the company's own expectations at the start of the year — as some deferrable procedures were affected by patient coverage and insurance premium dynamics, including the expiration of ACA (Affordable Care Act) enhanced premium subsidies. Additionally, U.S. bariatric procedure volumes declined in the high single digits, a trend management attributed in part to continued adoption of GLP-1 (glucagon-like peptide-1) obesity medications. International da Vinci procedures grew 20%, providing a bright spot, but not enough to shift the narrative.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should monitor several factors that will shape Intuitive Surgical's trajectory through the remainder of 2026 and into 2027.

Procedure Growth Sustainability: The company maintained its 13.5% to 15.5% da Vinci procedure growth outlook for the full year, which implies that second-half growth must remain within this range. Any further softening in U.S. deferrable procedures or international markets like China — where tender volumes and competitive pressures remain dynamic — could test the lower end of that band. Conversely, continued momentum in general surgery, after-hours procedures, and non-urology specialties internationally could provide upside.

da Vinci 5 Upgrade Cycle: With an installed base of over 1,700 da Vinci 5 systems and utilization running approximately 11% higher than the legacy Xi system, the upgrade cycle remains a multi-year catalyst for both system placements and recurring instrument revenue. The pace at which existing customers trade in older systems for da Vinci 5 will be a key metric to track.

Margin Trajectory and Extended Use Program: Management raised its non-GAAP gross profit margin forecast to a range of 68% to 69%, from a prior 67.5% to 68.5%, signaling confidence in operating leverage. However, the planned Extended Use Program for a subset of EndoWrist instruments, expected to begin in the first half of 2027, introduces a longer-term variable — while designed to lower customer cost per procedure and drive adoption in cost-constrained markets, it could modestly pressure instruments revenue per procedure over time.

Competitive Landscape: Competition in robotic surgery continues to intensify. Stryker's commercial launch of its Mako robotic power system and Medtronic's pursuit of expanded indications for its Hugo robotic-assisted surgery platform underscore a market where Intuitive's dominance, while formidable, faces growing challengers. How Intuitive maintains its competitive moat through innovation and clinical evidence will be critical to investor confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations